Pear Therapeutics

Five-year-old PEAR THERAPEUTICS recently claimed a major milestone in digital therapeutics: Last September, its flagship product, “reSET,” became the first software cleared by the FDA as a prescription product that helps treat a disease. The product—a mobile app for patients and a Web dashboard for clinicians—is designed to deliver cognitive behavioral therapy to substance-use-disorder patients in tandem with standard outpatient treatment programs. A randomized, 399-patient clinical trial showed that those who used reSET in combination with counseling had more success abstaining from using than a control group that received only face-to-face counseling.

Chris Guiffre, Pear Therapeutics • Photography by David Fox Photographer